                         SEQUENCE LISTING

<110>  Alba Therapeutics Corporation
 
<120>  Novel Inhibitors of Mammalian Tight Junction Opening

<130>  ALBA-042/01WO

<150>  US 60/981,399
<151>  2007-10-19

<160>  70    

<170>  PatentIn version 3.5

<210>  1
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  1

Gly Gly Val Leu Val Gln Pro Gly 
1               5               


<210>  2
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  2

Gly Val Leu Val Gln Pro Gly 
1               5           


<210>  3
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  3

Val Leu Val Gln Pro Gly 
1               5       


<210>  4
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  4

Leu Val Gln Pro Gly 
1               5   


<210>  5
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  5

Val Gln Pro Gly 
1               


<210>  6
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  6

Gln Pro Gly 
1               


<210>  7
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  7

Ala Pro Gly  
1               


<210>  8
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  8

Gln Ala Gly 
1               


<210>  9
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  9

Gln Pro Ala 
1               


<210>  10
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Gln may be D-Gln

<400>  10

Gln Pro Gly  
1               


<210>  11
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Pro may be D-Pro

<400>  11

Gln Pro Gly
1               


<210>  12
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Gln may be D-Gln

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Pro may be D-Pro

<400>  12

Gln Pro Gly
1               


<210>  13
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  13

Gly Pro Gln
1               


<210>  14
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Pro may be D-Pro

<400>  14

Gly Pro Gln 
1               


<210>  15
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Gln may be D-Gln

<400>  15

Gly Pro Gln
1               


<210>  16
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  Pro may be D-Pro

<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  Gln may be D-Gln

<400>  16

Gly Pro Gln
1               


<210>  17
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  17

Ala Pro Gly
1               


<210>  18
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  18

His Pro Gly 
1               


<210>  19
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  19

Asp Pro Gly 
1               


<210>  20
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  20

Arg Pro Gly 
1               


<210>  21
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  21

Phe Pro Gly  
1               


<210>  22
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  22

Gly Pro Gly 
1               


<210>  23
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  23

Glu Pro Gly 
1               


<210>  24
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  24

Lys Pro Gly
1               


<210>  25
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  25

Leu Pro Gly
1               


<210>  26
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  26

Met Pro Gly 
1               


<210>  27
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  27

Asn Pro Gly  
1               


<210>  28
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  28

Ser Pro Gly 
1               


<210>  29
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  29

Tyr Pro Gly 
1               


<210>  30
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  30

Thr Pro Gly
1               


<210>  31
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  31

Ile Pro Gly 
1               


<210>  32
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  32

Trp Pro Gly
1               


<210>  33
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  33

Pro Pro Gly 
1               


<210>  34
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  34

Val Pro Gly 
1               


<210>  35
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  35

Xaa Pro Gly 
1               


<210>  36
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  36

Xaa Val Gly
1               


<210>  37
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  37

Xaa Gln Gly
1               


<210>  38
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  38

Xaa Ser Gly 
1               


<210>  39
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  39

Xaa Lys Gly 
1               


<210>  40
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  40

Xaa Phe Gly
1               


<210>  41
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  41

Xaa Glu Gly
1               


<210>  42
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  42

Xaa Thr Gly
1               


<210>  43
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  43

Xaa Ile Gly
1               


<210>  44
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  44

Xaa Tyr Gly 
1               


<210>  45
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  45

Xaa His Gly 
1               


<210>  46
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  46

Xaa Asn Gly
1               


<210>  47
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  47

Xaa Arg Gly 
1               


<210>  48
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  48

Xaa Gly Gly 
1               


<210>  49
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  49

Xaa Trp Gly
1               


<210>  50
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  50

Xaa Asp Gly
1               


<210>  51
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  51

Xaa Met Gly
1               


<210>  52
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  52

Xaa Leu Gly 
1               


<210>  53
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  53

Xaa Pro Gln 
1               


<210>  54
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  54

Xaa Pro Asn
1               


<210>  55
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  55

Xaa Pro Gln 
1               


<210>  56
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  56

Xaa Pro Ser 
1               


<210>  57
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  57

Xaa Pro Pro 
1               


<210>  58
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  58

Xaa Pro Trp
1               


<210>  59
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  59

Xaa Pro Asp
1               


<210>  60
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  60

Xaa Pro His 
1               


<210>  61
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  61

Xaa Pro Leu
1               


<210>  62
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  62

Xaa Pro Arg 
1               


<210>  63
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  63

Xaa Pro Val 
1               


<210>  64
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  64

Xaa Pro Lys
1               


<210>  65
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  65

Xaa Pro Glu 
1               


<210>  66
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  66

Xaa Pro Phe
1               


<210>  67
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  67

Xaa Pro Ile 
1               


<210>  68
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  68

Xaa Pro Met
1               


<210>  69
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa may be pyroglutamic acid

<400>  69

Xaa Pro Tyr
1               


<210>  70
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tight junction antagonist

<400>  70

Phe Cys Ile Gly Arg Leu
1               5             



